Report of Foreign Issuer (6-k)
June 11 2019 - 6:02AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 6-K
REPORT OF
FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE
SECURITIES EXCHANGE ACT OF 1934
For the month of June 2019
Commission File Number: 001-31995
MEDICURE
INC.
(Translation of registrant's name into English)
2-1250 Waverley Street
Winnipeg, MB Canada R3T 6C6
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x
Form 40-F o
Indicate by check mark if the registrant is
submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o
Indicate by check mark if the registrant is
submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o
Indicate by check mark whether the registrant
by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule
12g3-2(b) under the Securities Exchange Act of 1934.
Yes o
No x
If “Yes” is marked, indicate below
the file number assigned to the registrant in connection with Rule 12g3-2(b): 8a72____.
EXHIBIT
LIST
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
Medicure Inc. |
|
(Registrant) |
|
|
|
|
|
Date: June 10, 2019 |
By: |
/s/ Dr. Albert D. Friesen |
|
Dr. Albert D. Friesen |
|
Title: President & CEO |
Exhibit 99.1
Medicure Announces Appoinment of Dr. Neil
Owens as President and Chief Operating Officer
WINNIPEG, June 10, 2019 /CNW/ - Medicure Inc.
("Medicure" or the "Company") (TSXV: MPH, OTC: MCUJD.PK), a pharmaceutical company, today announced
that Dr. Neil Owens has been appointed President and Chief Operating Officer of the Company effective July 1, 2019. In this
capacity, Dr. Owens will be responsible for implementing the Company's strategic plans, and overseeing day-to-day operations, including
the advancement and management of new and existing pharmaceutical products. Dr. Albert Friesen has served as the Company's President
since May of 2016 and will continue to serve as Chief Executive Officer of the Company and as Chair of its Board of Directors.
Dr. Neil Owens has worked at Medicure since
2014, in various positions of increasing responsibility, most recently as Director, Scientific Affairs. Dr. Owens holds a Bachelor
of Science and a Ph.D. in Chemistry from the University of Manitoba and has Post Doctoral experience with the IECB (the Institut
Européen de Chimie et Biologie, an international and interdisciplinary research team incubator, operating under
the joint authority of the CNRS, INSERN and the Université de Bordeaux).
"Dr. Owens has demonstrated leadership
skills and the drive to implement Medicure's growth and development strategy." stated Dr. Friesen. "We are pleased that
he is taking on this new executive management role."
About Medicure
Medicure is a pharmaceutical company focused
on the development and commercialization of therapies for the U.S. cardiovascular market. The present focus of the Company is the
marketing and distribution of AGGRASTAT® (tirofiban hydrochloride) injection, ZYPITAMAGTM (pitavastatin)
tablets and the ReDS™ device in the United States, where they are sold through the Company's U.S. subsidiary, Medicure Pharma
Inc. For more information on Medicure please visit www.medicure.com.
To be added to Medicure's e-mail list, please
visit:
http://medicure.mediaroom.com/alerts
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy
or accuracy of this release.
View
original content:http://www.prnewswire.com/news-releases/medicure-announces-appoinment-of-dr-neil-owens-as-president-and-chief-operating-officer-300864837.html
SOURCE Medicure Inc.
View original content: http://www.newswire.ca/en/releases/archive/June2019/10/c6052.html
%CIK: 0001133519
For further information: James Kinley, Chief Financial Officer,
Tel. 888-435-2220, Fax 204-488-9823, E-mail: info@medicure.com, www.medicure.com
CO: Medicure Inc.
CNW 17:30e 10-JUN-19
This regulatory filing also includes additional resources:
ex991.pdf
Medicure (PK) (USOTC:MCUJF)
Historical Stock Chart
From Aug 2024 to Sep 2024
Medicure (PK) (USOTC:MCUJF)
Historical Stock Chart
From Sep 2023 to Sep 2024